BACKGROUND: Several serum markers reflecting extracellular matrix status have been correlated with liver fibrosis in non-HIV-infected patients with chronic hepatitis C infection. These indexes have been less examined in HIV/HCV-coinfected individuals. OBJECTIVE: We aimed to evaluate the predictive value of serum markers for liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HVC). METHODS: Serum levels of metalloproteinases 1 and 2 (MMP-1 and -2), tissue inhibitors of matrix metalloproteinases (TIMP-1), procollagen type III N-terminal peptide (PIIINP), and hyaluronic acid (HA) were measured in HIV-infected patients with chronic hepatitis C at the time of obtaining a liver biopsy and before the consideration of anti-hepatitis C therapy. RESULTS: One hundred and nineteen consecutive HIV-HVC coinfected patients were included. TIMP-1 (r = 0.6; P < 0.001), TIMP-1/MMP-1 ratio (r = 0.5; P < 0.001), TIMP-1/MMP-2 ratio (r = 0.3; P < 0.001), MMP-2 (r = 0.2; P = 0.044), PIIINP (r = 0.4; P < 0.001), and HA (r = 0.5; P < 0.001) were positively and significantly correlated with the fibrosis stage. In the multivariate analysis, TIMP-1 (odds ratio [OR] = 1.004, 95% confidence interval [CI]: 1.002 to 1.006, P = 0.001) and HA >95 microg/dL (OR = 6.041, 95% CI: 1.184 to 30.816, P = 0.031) were independently associated with liver fibrosis. The area under the curve of score to discriminate mild (F0-F1) from significant (F2-F4) fibrosis in the received-operating analysis using the variables TIMP-1 and HA was 0.84, with a sensitivity of 72.9% and a specificity of 83.1%. CONCLUSION: TIMP-1 and HA were quite sensitive and specific for predicting the degree of liver fibrosis in HIV-infected patients with chronic hepatitis C. These parameters may become a noninvasive alternative to liver biopsy when the degree of liver fibrosis needs to be estimated.
BACKGROUND: Several serum markers reflecting extracellular matrix status have been correlated with liver fibrosis in non-HIV-infectedpatients with chronic hepatitis C infection. These indexes have been less examined in HIV/HCV-coinfected individuals. OBJECTIVE: We aimed to evaluate the predictive value of serum markers for liver fibrosis in HIV-infectedpatients with chronic hepatitis C virus (HVC). METHODS: Serum levels of metalloproteinases 1 and 2 (MMP-1 and -2), tissue inhibitors of matrix metalloproteinases (TIMP-1), procollagen type III N-terminal peptide (PIIINP), and hyaluronic acid (HA) were measured in HIV-infectedpatients with chronic hepatitis C at the time of obtaining a liver biopsy and before the consideration of anti-hepatitis C therapy. RESULTS: One hundred and nineteen consecutive HIV-HVC coinfectedpatients were included. TIMP-1 (r = 0.6; P < 0.001), TIMP-1/MMP-1 ratio (r = 0.5; P < 0.001), TIMP-1/MMP-2 ratio (r = 0.3; P < 0.001), MMP-2 (r = 0.2; P = 0.044), PIIINP (r = 0.4; P < 0.001), and HA (r = 0.5; P < 0.001) were positively and significantly correlated with the fibrosis stage. In the multivariate analysis, TIMP-1 (odds ratio [OR] = 1.004, 95% confidence interval [CI]: 1.002 to 1.006, P = 0.001) and HA >95 microg/dL (OR = 6.041, 95% CI: 1.184 to 30.816, P = 0.031) were independently associated with liver fibrosis. The area under the curve of score to discriminate mild (F0-F1) from significant (F2-F4) fibrosis in the received-operating analysis using the variables TIMP-1 and HA was 0.84, with a sensitivity of 72.9% and a specificity of 83.1%. CONCLUSION:TIMP-1 and HA were quite sensitive and specific for predicting the degree of liver fibrosis in HIV-infectedpatients with chronic hepatitis C. These parameters may become a noninvasive alternative to liver biopsy when the degree of liver fibrosis needs to be estimated.
Authors: Alba Diaz; Felipe García; Anna Mozos; Miguel Caballero; Agathe León; Antonio Martinez; Cristina Gil; Montserrat Plana; Teresa Gallart; Jose M Gatell; Llúcia Alós Journal: J Infect Dis Date: 2011-03-15 Impact factor: 5.226
Authors: Salvador Resino; José M Bellón; Cristina Asensio; Dariela Micheloud; Pilar Miralles; Ana Vargas; Pilar Catalán; Juan C López; Emilio Alvarez; Jaime Cosin; Raquel Lorente; María A Muñoz-Fernández; Juan Berenguer Journal: BMC Infect Dis Date: 2010-08-19 Impact factor: 3.090
Authors: Lars Peters; Jacqueline Neuhaus; Amanda Mocroft; Vincent Soriano; Jürgen Rockstroh; Gregory Dore; Massimo Puoti; Ellen Tedaldi; Bonaventura Clotet; Bernd Kupfer; Jens D Lundgren; Marina B Klein Journal: Antivir Ther Date: 2011
Authors: Christian Jansen; Diana J Leeming; Mattias Mandorfer; Inger Byrjalsen; Robert Schierwagen; Philipp Schwabl; Morten A Karsdal; Evrim Anadol; Christian P Strassburg; Jürgen Rockstroh; Markus Peck-Radosavljevic; Søren Møller; Flemming Bendtsen; Aleksander Krag; Thomas Reiberger; Jonel Trebicka Journal: PLoS One Date: 2014-09-29 Impact factor: 3.240
Authors: Sophie Seang; Anoma Somasunderam; Maitreyee Nigalye; Ma Somsouk; Timoty W Schacker; Joyce L Sanchez; Peter W Hunt; Netanya S Utay; Jordan E Lake Journal: Pathog Immun Date: 2017-06-21
Authors: Julio Collazos; Eulalia Valle-Garay; Tomás Suárez-Zarracina; Angel-Hugo Montes; José A Cartón; Víctor Asensi Journal: World J Virol Date: 2017-05-12
Authors: Laura Pérez-Is; Julio Collazos; Belén de la Fuente; Luis Morano; Maria Rivas-Carmenado; Manuel Rodriguez; Adolfo Romero-Favela; Galilea de Jesús Fonseca-González; Santiago Melón; Eulalia Valle-Garay; Víctor Asensi Journal: Sci Rep Date: 2022-03-09 Impact factor: 4.379